PMID- 18928518
OWN - NLM
STAT- MEDLINE
DCOM- 20100603
LR  - 20181113
IS  - 1756-8722 (Electronic)
IS  - 1756-8722 (Linking)
VI  - 1
DP  - 2008 Oct 17
TI  - Persistence of TEL-AML1 fusion gene as minimal residual disease has no additive 
      prognostic value in CD 10 positive B-acute lymphoblastic leukemia: a FISH study.
PG  - 17
LID - 10.1186/1756-8722-1-17 [doi]
AB  - OBJECTIVES: We have analyzed t(12;21)(p13:q22) in an attempt to evaluate the 
      frequency and prognostic significance of TEL-AML1 fusion gene in patients with 
      childhood CD 10 positive B-ALL by fluorescence in situ hybridization (FISH). 
      Also, we have monitored the prognostic value of this gene as a minimal residual 
      disease (MRD). METHODS: All bone marrow samples of eighty patients diagnosed as 
      CD 10 positive B-ALL in South Egypt Cancer Institute were evaluated by 
      fluorescence in situ hybridization (FISH) for t(12;21) in newly diagnosed cases 
      and after morphological complete remission as a minimal residual disease (MRD). 
      We determined the prognostic significance of TEL-AML1 fusion represented by 
      disease course and survival. RESULTS: TEL-AML1 fusion gene was positive in 
      (37.5%) in newly diagnosed patients. There was a significant correlation between 
      TEL-AML1 fusion gene both at diagnosis (r = 0.5, P = 0.003) and as a MRD (r = 
      0.4, P = 0.01) with favorable course. Kaplan-Meier curve for the presence of 
      TEL-AML1 fusion at the diagnosis was associated with a better probability of 
      overall survival (OS); mean survival time was 47 +/- 1 month, in contrast to 28 
      +/- 5 month in its absence (P = 0.006). Also, the persistence at TEL-AML1 fusion 
      as a MRD was not significantly associated with a better probability of OS; the 
      mean survival time was 42 +/- 2 months in the presence of MRD and it was 40 +/- 1 
      months in its absence. So, persistence of TEL-AML1 fusion as a MRD had no 
      additive prognostic value over its measurement at diagnosis in terms of 
      predicting the probability of OS. CONCLUSION: For most patients, the presence of 
      TEL-AML1 fusion gene at diagnosis suggests a favorable prognosis. The present 
      study suggests that persistence of TEL-AML1 fusion as MRD has no additive 
      prognostic value.
FAU - Mosad, Eman
AU  - Mosad E
AD  - Clinical Pathology Department, South Egypt Cancer Institute, Assiut University, 
      Assiut, Egypt. eman_mosaad@hotmail.com
FAU - Hamed, Hosny B
AU  - Hamed HB
FAU - Bakry, Rania M
AU  - Bakry RM
FAU - Ezz-Eldin, Azza M
AU  - Ezz-Eldin AM
FAU - Khalifa, Nesrine M
AU  - Khalifa NM
LA  - eng
PT  - Journal Article
DEP - 20081017
PL  - England
TA  - J Hematol Oncol
JT  - Journal of hematology & oncology
JID - 101468937
RN  - 0 (Core Binding Factor Alpha 2 Subunit)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (TEL-AML1 fusion protein)
SB  - IM
MH  - Child
MH  - Child, Preschool
MH  - Core Binding Factor Alpha 2 Subunit/*genetics
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Neoplasm, Residual/diagnosis/genetics
MH  - Oncogene Proteins, Fusion/*genetics
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis/*genetics
MH  - Prognosis
PMC - PMC2577682
EDAT- 2008/10/22 09:00
MHDA- 2010/06/04 06:00
PMCR- 2008/10/17
CRDT- 2008/10/22 09:00
PHST- 2008/09/09 00:00 [received]
PHST- 2008/10/17 00:00 [accepted]
PHST- 2008/10/22 09:00 [pubmed]
PHST- 2010/06/04 06:00 [medline]
PHST- 2008/10/22 09:00 [entrez]
PHST- 2008/10/17 00:00 [pmc-release]
AID - 1756-8722-1-17 [pii]
AID - 10.1186/1756-8722-1-17 [doi]
PST - epublish
SO  - J Hematol Oncol. 2008 Oct 17;1:17. doi: 10.1186/1756-8722-1-17.